Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$0.00$0.00— vs Q3 2016 Net Income-$679.08K-$679.08KN/M vs Q3 2016 EPS Diluted$0.00$0.00N/M vs Q3 2016 Operating Income-$681,166N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Sep 30, 2017 · filed Oct 31, 2017 · 31 d after period end